结核分枝杆菌药物作用机理及耐药机制研究进展  

Research progress on the drug action and resistance mechanism in Mycobacterium tuberculosis

作　　者：葛赛 宋欣怡 姜惠跃 李昭阳 朱壮彦[2] 孙曼銮 GE Sai;SONG Xin-yi;JIANG Hui-yue;LI Zhao-yang;ZHU Zhuang-yan;SUN Man-luan(Academic Journal Center,Shanxi Datong University,Datong 037009,China;Laboratory of Medical Biology,School of Medicine,Shanxi Datong University,Datong 037009,China;Laboratory of Molecular Biology,National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD 20892,USA)

机构地区：[1]山西大同大学学术期刊中心,山西大同037009 [2]山西大同大学医学院医学生物学实验室,山西大同037009 [3]美国国立卫生研究院糖尿病消化与肾病研究所分子生物学实验室,马里兰州贝什斯达20892

出　　处：《海南医学院学报》2023年第24期1904-1913,共10页Journal of Hainan Medical University

基　　金：山西省基础研究计划(202103021223339,20210302124435),山西省回国留学人员科研资助项目(2022‑175);山西大同大学青年科研基金(2019Q2,2019Q4);山西大同大学博士科研启动金(2018‑B‑13,2018‑B‑28)。

摘　　要：结核病(Tuberculosis,TB)是由结核分枝杆菌(Mycobacterium tuberculosis,MTB)引起的慢性、严重致死性传染病,也是当下仅次于新冠病毒肺炎的第二大单一传染源致死原因。伴随着抗生素滥用和抗结核药物的不规范使用,多耐药(multidrug-resistant,MDR)、泛耐药(extensively drug-resistant,XDR)和全耐药(totally drug-resistant,TDR)结核病的出现已成为全世界范围内结核病疫情消灭的障碍。据世界卫生组织统计,我国仍是全球结核病高负担国家之一,也是MDR结核病流行严重的国家之一。传统药物已无法满足现阶段结核病的控制,抗结核药物新靶点的发现和新型抗结核药物的研发已迫在眉睫。本文对传统和目前新研发的抗结核药物的作用机制进行了阐述,着重介绍了已知耐药机制的新进展,以期为开发新的抗结核药物提供新思路,降低结核病对社会的危害。Tuberculosis(TB)is a chronic infectious disease caused by Mycobacterium tuberculosis(MTB).It is the second largest single cause of death besides novel coronavirus pneumonia.Along with the abuse of antibiotics and extensive use of antituberculosis drugs,multidrug-resistant(MDR)TB,extensive drug-resistant(XDR)TB and totally drug-resistant(TDR)TB became obstacles to the tuberculosis eradication worldwide.According to the World Health Organization statistics,China is not only a high burden tuberculosis country in the world,but also a country with a serious epidemic of MDR.Traditional drugs fail to meet the needs of tuberculosis control.Therefore,it is urgent to find new targets of anti-tuberculosis drugs and develop new antituberculosis drugs.Hence,this paper systematically summarizes the mechanism of traditional and newly developed anti-tuberculosis drugs,in which the research progress of drug resistance mechanisms are mainly focused.This work provides us with new insights of new anti-tuberculosis drug developments,and may contribute to a reduction in the harm that tuberculosis brings to society.

关 键 词：抗结核药物 结核分枝杆菌 耐药机制 多耐药结核 

分 类 号：R378.911[医药卫生—病原生物学]